XML 27 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9
Development, Commercialization and Supply Agreement - Additional Information (Detail) (USD $)
3 Months Ended 0 Months Ended
Mar. 31, 2015
Feb. 26, 2015
License And Collaboration Agreements [Line Items]    
Licensing revenue $ 375,000us-gaap_LicensesRevenue  
Eddingpharm    
License And Collaboration Agreements [Line Items]    
Non-refundable up-front received   15,000,000amrn_NonRefundableUpfrontPaymentsReceived
/ amrn_BusinessDevelopmentsAxis
= amrn_EddingpharmMember
Deferred revenue 14,600,000us-gaap_DeferredRevenue
/ amrn_BusinessDevelopmentsAxis
= amrn_EddingpharmMember
 
Eddingpharm | Up-front Payment    
License And Collaboration Agreements [Line Items]    
Licensing revenue 400,000us-gaap_LicensesRevenue
/ amrn_BusinessDevelopmentsAxis
= amrn_EddingpharmMember
/ us-gaap_DeferredRevenueArrangementTypeAxis
= us-gaap_UpFrontPaymentArrangementMember
 
Eddingpharm | Maximum    
License And Collaboration Agreements [Line Items]    
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone   $ 154,000,000amrn_EligibleMilestonePayment
/ amrn_BusinessDevelopmentsAxis
= amrn_EddingpharmMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember